Redeye ceases its coverage of Asarina Pharma due to the end of the contractual period.
Redeye provides a short comment on the Q4 report published by Asarina Pharma earlier today.
The initiation of Asarina Pharma’s phase IIa study in Tourette’s has been postponed until December 2021 due to an administrative backlog at ...
There are no big surprises in the Q2’21 financials of Asarina Pharma.
